Objectives: This investigation compared patients undergoing lobectomy for non-small cell lung cancer by either a general surgeon or a cardiothoracic surgeon across a geographically diverse system of hospitals to see whether a significant difference in quality or cost was present.
Methods: The Premiere administrative database and tumor registry data of a single health system's hospitals was used to compare adherence to national treatment guidelines, patient outcomes, and charges for patients undergoing lobectomy for non-small cell lung cancer in a 5-year period. Surgeons performing lobectomy were designated as a general surgeon or cardiothoracic surgeon according to their national provider number and board certification status. Excluded from analysis were centers that performed fewer than 50 lobectomies during the study period.
Results: During the study period, 2823 lobectomies were performed by 46 general surgeons and 3653 lobectomies were performed by 29 cardiothoracic surgeons in 54 hospitals in a single health care system. Significant differences were found between general and cardiothoracic surgeons with respect to adherence to national guidelines in staging and treatment, mean length of stay, significant morbidity, and operative mortality. Mean charges for lobectomy of the lung were also found to differ significantly between general and cardiothoracic surgeons.
Conclusions: This review found that currently measurable indicators for quality of care were significantly superior and overall charges were significantly reduced when a lobectomy for non-small cell lung cancer was performed by a cardiothoracic surgeon rather than by a general surgeon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtcvs.2012.09.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Robotic Portal Segmentectomy in the Right Middle Lobe After Right Upper Lobectomy.
Ann Thorac Surg Short Rep
December 2024
Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan.
Although segmentectomy is the standard surgical procedure for small-sized peripheral non-small cell lung cancer, reports on segmentectomy for right middle robe are rare because of the anatomical feature. We report a case of an 81-year-old woman with a history of left S4 segmentectomy, left basal segmentectomy, and right upper lobectomy for multiple primary lung cancer with a part solid nodule in S4a. Owing to the increased volume of the right middle lobe following a right upper lobectomy, a right S4 segmentectomy was performed.
View Article and Find Full Text PDFSignificance of Pulmonary Artery Dilatation in Lung Cancer Patients With Chronic Obstructive Pulmonary Disease Who Underwent Pulmonary Resection.
Ann Thorac Surg Short Rep
September 2024
Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka, Japan.
Background: The significance of pulmonary artery (PA) diameter in patients with non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) who undergo pulmonary resection has not been elucidated.
Methods: Data of 357 patients with NSCLC and COPD who underwent pulmonary resection were retrospectively reviewed. The main PA diameter, determined by preoperative computed tomography, relative to the body surface area (PBR), was used as an index of PA dilatation, and patients were divided into 2 groups using median values.
Segmentectomy vs Lobectomy for Non-Small Cell Lung Cancer: The Impact of Tumor Location.
Ann Thorac Surg Short Rep
September 2024
Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California.
Background: The technical complexity of segmentectomy and preservation of lung parenchyma compared with lobectomy vary by lobe. This study evaluated the impact of non-small cell lung cancer tumor location on segmentectomy use and outcomes.
Methods: Outcomes after lobectomy or segmentectomy for cT1N0M0 (≤2 cm) non-small cell lung cancer patients stratified by tumor location in smaller (right upper/middle) vs larger (bilateral lower/left upper) lobes were evaluated with logistic regression, Kaplan-Meier curves, and Cox proportional hazards methods.
Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy.
Ann Thorac Surg Short Rep
September 2024
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Background: The real-world safety of robotic resections after neoadjuvant chemoimmunotherapy remains poorly defined in patients with non-small cell lung cancer. Due to reported increased operative challenges after neoadjuvant immunotherapy, we aim to describe our early institutional experience and outcomes after robotic resection in this clinical context.
Methods: We performed a retrospective chart review of patients with non-small cell lung cancer who underwent a robotic lobectomy, comparing patients from June 1, 2022, through October 31, 2023, who were treated with neoadjuvant chemoimmunotherapy consistent with the Checkmate-816 protocol and a control group with upfront resection.
The Necessity of Lymphadenectomy for Non-Small Cell Lung Cancer Smaller Than 6 mm in Solid Size.
Ann Surg Oncol
January 2025
Department of Thoracic Surgery, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: This study aimed to evaluate the necessity of lymph node sampling for specific non-small cell lung cancer (NSCLC).
Methods: Patients with small-size (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened. The characteristics of patients with nodal metastasis were demonstrated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!